[Pharmacotherapy of central oculomotor disorders].
Nystagmus causes blurred vision due to oscillopsia, as well as impaired balance. Depending on etiology, additional cerebellar and brain stem signs may occur. We present the current pharmacotherapy of the most common forms of central nystagmus: downbeat nystagmus (DBN), upbeat nystagmus (UBN), acquired pendular nystagmus (APN), and congenital nystagmus (CGN). Recommended medical therapies are aminopyridines (4-AP) for DBN and UBN, gabapentin and memantine for CGN and APN, and baclofen for periodic alternating nystagmus (PAN).
Kalla
R
R
Neurologische Klinik, Klinikum Grosshadern Ludwig-Maximilians-Universität (LMU) München, Marchioninistr. 15, 81377, München. Roger.Kalla@med.uni-muenchen.de
Spiegel
R
R
Wagner
J
J
Rettinger
N
N
Jahn
K
K
Strupp
M
M
D015761:4-Aminopyridine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077770:Amifampridine; D000588:Amines / Q000627:therapeutic use; D001418:Baclofen / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000077206:Gabapentin; D006801:Humans; D008279:Magnetic Resonance Imaging; D008559:Memantine / Q000627:therapeutic use; D009759:Nystagmus, Pathologic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014726:Vestibular Nuclei / Q000187:drug effects / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D015761:4-Aminopyridine; D001418:Baclofen; D000077770:Amifampridine; D008559:Memantine